Opus Genetics, Inc.
Opus Genetics, Inc. (IRD) Revenue
Annual & quarterly revenue history · segment & region breakdown
IRD · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsOpus Genetics, Inc. trailing twelve-month (TTM) revenue is $0.01B, an increase of 29.15% year-over-year from $0.01B in FY2025.
Revenue trend
2025 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.01B | +$0.00B | +29.15% |
| 2024-12-31 | $0.01B | -$0.01B | -42.30% |
| 2023-12-31 | $0.02B | -$0.02B | -52.20% |
| 2022-12-31 | $0.04B | +$0.04B | +6665.70% |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Opus Genetics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Opus Genetics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Opus Genetics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
IRD revenue · 4 questionsIRD's trailing twelve-month (TTM) revenue is $0.01B. That is an increase of 29.15% year-over-year from $0.01B in FY2025.
▸ Source: FMP · Opus Genetics, Inc. SEC filings · GAAP · Opus Genetics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026